| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 1/200 - 1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | MLP; SMUC; MUC-2 |
| Entrez GeneID | 4583 |
| clone | 4A5G8 |
| WB Predicted band size | 540kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human MUC2 (AA: 4373-4557) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是3篇关于MUC2抗体的文献摘要概览：
---
1. **文献名称**: *"Production and characterization of a monoclonal antibody against human MUC2 mucin"*
**作者**: Buisine MP, et al.
**摘要**: 该研究报道了一种新型抗人MUC2黏蛋白单克隆抗体的开发，验证了其在免疫组化中对正常结肠和结直肠肿瘤组织黏液分泌的特异性识别，并证明其可用于区分MUC2与其他黏蛋白家族成员。
2. **文献名称**: *"MUC2 mucin expression in intestinal metaplasia, dysplasia, and gastric cancer"*
**作者**: Reis CA, et al.
**摘要**: 利用MUC2抗体研究胃黏膜病变，发现MUC2在肠化生和胃癌中异常表达，提示其作为肠型胃癌的生物标志物潜力，并探讨了抗体在病理诊断中的应用价值。
3. **文献名称**: *"Antibody-based detection of MUC2 mucin in fecal samples for colorectal cancer screening"*
**作者**: Holmberg Å, et al.
**摘要**: 研究开发了一种基于MUC2抗体的粪便免疫检测方法，用于非侵入性结直肠癌筛查，验证了其在早期癌变患者中检测黏液分泌异常的敏感性和特异性。
---
以上文献涵盖抗体开发、病理机制及临床诊断应用方向，均聚焦MUC2抗体的特异性与应用场景。如需具体期刊信息或发表年份，可进一步补充检索关键词。
The MUC2 antibody targets mucin 2 (MUC2), a high-molecular-weight, gel-forming glycoprotein central to mucosal protection. MUC2. a member of the secreted mucin family, is predominantly expressed by goblet cells in the intestinal and respiratory tracts. It forms the structural backbone of the mucus layer, shielding epithelial surfaces from pathogens, toxins, and mechanical stress. Structurally, MUC2 contains a central O-glycosylated tandem repeat domain flanked by cysteine-rich regions that facilitate polymerization. Its dysregulation is linked to diseases like inflammatory bowel disease (IBD), colorectal cancer, and respiratory disorders.
MUC2 antibodies are essential tools in research and diagnostics. They enable detection of MUC2 expression patterns in tissues, aiding in studies of mucus barrier integrity, tumor progression (e.g., MUC2 downregulation in colorectal cancer), and microbial interactions. Commercially available antibodies are often raised against the tandem repeat or variable number tandem repeat (VNTR) regions, with specificity validated via immunohistochemistry (IHC), Western blot, or immunofluorescence (IF). Challenges include cross-reactivity due to shared epitopes among mucins and variability in glycosylation states.
Clinically, MUC2 antibodies help differentiate adenocarcinomas (e.g., intestinal vs. non-intestinal origins) and assess mucinous carcinoma biomarkers. Emerging therapeutic strategies explore targeting MUC2 for drug delivery or immunotherapy. However, standardization of antibody validation and interpretation remains critical for reproducibility.
×
